Bristol Myers' (BMY) sBLA for Orencia Gets FDA Priority Review

Mohit Chouhan August 25, 2021
The FDA accepts Bristol Myers' (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict...


Post a Comment

0 Comments